Effects of ginseol k-g3, an rg3-enriched fraction, on scopolamine-induced memory impairment and learning deficit in mice

Journal of Ginseng Research

Volumn 38, Issue 1, 2014, Pages 1-7

  Peña, Ike Dela ^a   Yoon, Seo Young ^a   Kim, Hee Jin ^a   Park, Sejin ^b   Hong, Eun Young ^c   Ryu, Jong Hoon ^b   Park, Il Ho ^a   Cheong, Jae Hoon ^a  

^a Sahmyook University   (South Korea)

^b Kyung Hee University   (South Korea)

^c CJ Corporation   (South Korea)

Author keywords

Ginseol k g3; Memory; Panax ginseng; Rg3; Scopolamine

Indexed keywords

ACETYLCHOLINESTERASE; DONEPEZIL; GINSENG EXTRACT; GINSENOSIDE; GINSENOSIDE RG 3; GINSEOL K G3; SCOPOLAMINE; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; ENZYME ACTIVITY; FRACTIONATION; GINSENG; IN VITRO STUDY; IN VIVO STUDY; LATENT PERIOD; LEARNING DISORDER; LOCOMOTION; MALE; MEMORY DISORDER; MORRIS WATER MAZE TEST; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; SIGNAL TRANSDUCTION; SWIMMING; TASK PERFORMANCE; Y-MAZE TEST;

EID: 84892987305     PISSN: 12268453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jgr.2013.11.003     Document Type: Article

References (42)

1. Koo EH, Lansbury PT, Kelly JW. Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proc Natl Acad Sci USA 1999;96:9989-90.
2. Terry RD. The fine structure of neurofibrillary tangles in Alzheimer's disease. J Neuropathol Exp Neurol 1963;22:629-42.
3. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351-7.
4. Bartus RT, Dean 3rd RL, Beer B, Lippa A. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-17.
5. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-47.
6. Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev Neurother 2008;8:1703-18.
7. Terry Jr AV, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003;306:821-7.
8. Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS. Persistent treatment with cholinesterase inhibitors and/or memantine shows clinical progression of Alzheimer disease. Alzheimers Res Ther 2009;1:7.
9. Jeong SM, Nah SY. Ginseng and ion channels: are ginsensosides, active component of Panax ginseng, differential modulator of ion channels? J Ginseng Res 2005;29:19-26.
10. Park JD, Kim DS, Kwon HY, Son SK, Lee YH, Baek NI, Kim SI, Rhee DK. Effectsofginseng saponin on modulation of multidrug resistance. Arch Pharm Res 1996;19:213-8.
11. Mook JI, Hong HS, Boo JH, Lee KH, Yun SH, Cheong MY, Joo I, Huh K, Jung MW. Ginsenoside Rb1 and Rg1 improve spatial learning and increase hippocampal synaptophysin level in mice. J Neurosci Res 2001;63:509-15.
12. Saito H. Effects of ginsenoside Rb1 and ginsenoside Rg1 on learning and memory. In: Shibata S, Ohtsuka Y, Saito H, editors. Recent advances in ginseng study. Tokyo: Hirokawa Publishing; 1990. p. 99.
13. Yamaguchi Y, Haruta K, Kobayashi H. Effects of ginsenosides on impaired performance induced in the rat by scopolamine in a radial-arm maze. Psychoneuroendocrinology 1995;20:645-53.
14. Tohda C, Matsumoto N, Zou K, Meselhy MR, Komatsu K. Ab(25-35)- induced memory impairment, axonal atrophy, and synaptic loss are ameliorated by M1, a metabolite of protopanaxadiol-type saponins. Neuropsychopharmacology 2004;29:860-8.
15. Zhang JT, Qu ZW, Liu Y, Deng HL. Preliminary study on antiamnesic mechanism of Rg1 and Rb1. Chin Med J 1990;103:932-8.
16. Liao B, Newmark H, Zhou R. Neuroprotective effects of ginseng total saponin and ginsenosides Rb1 and Rg1 on spinal cord neurons in vitro. Experiment Neurol 2002;173:224-34.
17. Nishiyama N, Cho SI, Kitagawa I, Saito H. Malonyl-ginsenoside Rb1 potentiates nerve growth factor (NGF)-induced neurite outgrowth of cultured chick embryonic dorsal root ganglia. Biol Pharmacol Bull 1994;17:509-13.
18. Bao HY, Zhang J, Yeo SJ, Myung CS, Kim HM, Kim JM, Park JH, Cho JS, Kang JS. Memory enhancing and neuroprotective effects of selected ginsenosides. Arch Pharm Res 2005;28:335-42.
19. Fang F, Chen X, Huang T, Lue LF, Luddy JS, Yan SS. Multi-faced neuroprotective effects of Ginsenoside Rg1 in an Alzheimer mouse model. Biochim Biophys Acta 2012;1822:286-92.
20. Yang JH, Han SJ, Ryu JH, Kang IS, Kim DH. Ginsenoside Rh2 ameliorates scopolamine-induced learning deficit in mice. Biol Pharm Bull 2009;32: 1710-5.
21. Klinkenberg I, Blokland A. The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci Biobehav Rev 2010;34:1307-50.
22. Kim S, Rhim H. Ginsenosides inhibit NMDA receptor-mediated epileptic discharges in cultured hippocampal neurons. Arch Pharm Res 2004;27:524-30.
23. Kim JH, Kim S, Yoon IS, Lee JH, Jang BJ, Jeong SM, Lee JH, Lee BH, Han JS, Oh S, et al. Protective effects of ginseng saponins on 3-nitropropionic acid-induced striatal degeneration in rats. Neuropharmacology 2005;48:743-56.
24. Roh YS, Kim HB, Kang CW, Kim BS, Nah SY, Kim JH. Neuroprotective effects of ginsenoside Rg3 against 24-OH-cholesterol-induced cytotoxicity in cortical neurons. J Ginseng Res 2010;34:246-53.
25. Tian J, Fu F, Geng M, Jiang Y, Yang J, Jiang W, Wang C, Liu K. Neuroprotective effect of 20(S)-ginsenoside Rg3 on cerebral ischemia in rats. Neurosci Lett 2005;374:92-7.
26. Kim S, Ahn K, Oh TH, Nah SY, Rhim H. Inhibitory effect of ginsenosides on NMDA receptor-mediated signals in rat hippocampal neurons. Biochem Biophys Res Commun 2002;296:247-54.
27. Chen F, Eckman E, Eckman C. Reductions in levels of the Alzheimer's amyloid b peptide after oral administration of ginsenosides. FASEB J 2006;20:1269-71.
28. In JG, Lee BS, Kim EJ, Park MH, Yang DC. Increase of functional saponin by acidic treatment and temperature of red ginseng extract. Korea J Plant Res 2006;19:139-43.
29. Kim DH, Jeon SJ, Son KH, Jung JW, Lee SJ, Yoon BH, Lee JJ, Cho YW, Cheong JH, Ko KH, et al. The ameliorating effect of oroxylin A on scopolamine-induced memory impairment in mice. Neurobiol Learn Mem 2007;87:536-46.
30. Lee YJ, Choi DY, Han SB, Kim YH, Kim KH, Seong YH, Oh KW, Hong TJ. A comparison between extract products of Magnolia officinalis on memory impairment and amyloidogenesis in a transgenic mouse model of Alzheimer's disease. Biomol Ther 2012;20:332-9.
31. Kim SR, Kang SY, Lee KY, Kim SH, Markeloni GJ, Oh TH, Kim CK. Anti-amnesic activity of E-p-methoxycinnamic acid from Scrophularia buergeriana. Brain Res Cog Brain Res 2003;17:454-61.
32. Ellman GL, Courtney KD, Andres V, Feather-Stone RM. A new and rapid colormetric determination of cholinesterase activity. Biochem Pharmacol 1961;7:88-95.
33. Park SJ, Jung JM, Lee HE, Lee YW, Kim DH, Kim JM, Hong JG, Lee CH, Jung IH, Cho YB, et al. The memory ameliorating effects of INM-176, an ethanolic extract of Angelica gigas, against scopolamine- or Ab1-42-induced cognitive dysfunction in mice. J Ethnopharmacology 2012;143:611-20.
34. Olton DS, Papas BC. Spatial memory and hippocampal function. Neuropsychologia 1979;17:669-82.
35. Lorenzini CA, Baldi E, Bucherelli C, Sacchetti B, Tassoni G. Role of dorsal hippocampus in acquisition, consolidation and retrieval of rat's passive avoidance response: a tetrodotoxin functional inactivation study. Brain Res 1996;730: 32-9.
36. Barnes CA, Danysz W, Parsons CG. Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, shortterm exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 1996;8:565-71.
37. Morris RG. Development of a water maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984;11:47-60.
38. Buccafusco JJ. The revival of scopolamine reversal for the assessment of cognition-enhancing drugs. In: Buccafusco JJ, editor. Methods of behavior analysis in neuroscience. 2nd ed. Florida: CRC Press; 2009. Ch. 17:329-43.
39. Rossor M, Iversen LL. Non-cholinergic neurotransmitter abnormalities in Alzheimer's disease. Brit Med Bull 1986;42:70-4.
40. Takada Y, Yonezawa A, Kume T, Katsuki H, Kaneko S, Sugimoto H, et al. Nicotinic acetylcholine receptor-mediated neuroprotection by donezepil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther 2003;306:772-7.
41. Fan Y, Hu J, Li J, Yang Z, Xin X, Wang J, Ding J, Geng M. Effect of acidic oligosaccharide sugar chain on scopolamine-induced memory impairment in rats and its related mechanisms. Neurosci Lett 2005;374:222-6.
42. Kim EJ, Jung IH, Van Le TK, Jeong JJ, Kim NJ, Kim DH. Ginsenoside Rg5 and Rh3 protect scopolamine-induced memory deficits in mice. J Ethnopharmacol 2013;146:294-9.